⚕ GalenOps CRO console
← SITE008 (KOR)

SITE008-0058

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE008 (KOR) (Dr. Kim) · consented 2022-05-02
Adverse events
9
Serious AEs
2
Open data queries
0
Luna dropout signal
–

Adverse events

severe serious assessed 2026-08-18

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-30 (study day 261); relationship: not assessed; serious criteria: hospitalization

moderate assessed 2026-08-18

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-08-25 (study day 468); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-03-28 (study day 684); relationship: N

moderate assessed 2026-08-18

Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-06-02 (study day 750); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-07-24 (study day 802); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-08-07 (study day 816); relationship: not assessed

severe assessed 2026-08-18

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2024-08-17 (study day 826); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-10-11 (study day 881); relationship: N; serious criteria: hospitalization

moderate assessed 2026-08-18

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2025-01-03 (study day 965); relationship: N

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.